Biopharmaceutical
Biotechnology
Medical

Dynavax

$7.10
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.07 (-0.98%) Today
-$0.07 (-0.98%) Today

Why Robinhood?

You can buy or sell Dynavax and other stocks, options, ETFs, and crypto commission-free!

About

Dynavax Technologies Corporation Common Stock, also called Dynavax, is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. Read More It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.

Employees
249
Headquarters
Berkeley, California
Founded
1996
Market Cap
450.72M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.25M
High Today
$7.27
Low Today
$7.04
Open Price
$7.24
Volume
79.13K
52 Week High
$22.80
52 Week Low
$6.75

Collections

Biopharmaceutical
Biotechnology
Medical
Pharmaceutical
Health
Cancer Prevention
Therapy
Technology

News

Simply Wall StMar 21

Should You Worry About Dynavax Technologies Corporation’s (NASDAQ:DVAX) CEO Pay?

Eddie Gray has been the CEO of Dynavax Technologies Corporation (NASDAQ:DVAX) since 2013. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization.

224
Seeking AlphaMar 13

Dynavax Technologies (DVAX) Presents At Cowen and Company 39th Annual Health Care Conference - Slideshow

The following slide deck was published by Dynavax Technologies Corporation in conjunction with this event. 1 20 Click to enlarge Notes:...

5
The Motley FoolMar 7

Why Dynavax Technologies Cratered in February

What happened Shares of Dynavax Technologies (NASDAQ:DVAX), a vaccine and immuno-oncology specialist, dropped by 15.9% last month, according to data from S&P Global Market Intelligence. What sparked this sell-off? Dynavax's stock tanked after the company reported its fourth-quarter and full-year results toward the end of February. While the biotech actually beat Wall Street's consensus estimate on revenue for the fourth quarter, investors were apparently hoping the company would announce a partnering deal...

404

Earnings

-$0.65
-$0.54
-$0.44
-$0.33
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.